UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 185

Sortiert nach

BRCA1/2 testing: therapeutic implications for breast cancer management

British journal of cancer, 2018-07, Vol.119 (2), p.141-152

2018

Link zum Volltext

Verfügbarkeit prüfen

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Journal of clinical oncology, 2020-12, Vol.38 (36), p.4274-4282

2020

Link zum Volltext

Verfügbarkeit prüfen

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline

Journal of clinical oncology, 2020-06, Vol.38 (18), p.2080-2106

2020

Link zum Volltext

Verfügbarkeit prüfen

Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis

Breast cancer research : BCR, 2019-09, Vol.21 (1), p.107-107, Article 107

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1145-1153

2010

Link zum Volltext

Verfügbarkeit prüfen

Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer

Journal of clinical oncology, 2015-03, Vol.33 (9), p.969-971

2015

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update

Journal of clinical oncology, 2021-09, Vol.39 (26), p.2959-2961

2021

Link zum Volltext

Verfügbarkeit prüfen

Noncontrast CMR for Detecting Early Myocardial Tissue Injury in a Swine Model of Anthracycline-Induced Cardiotoxicity

JACC. Cardiovascular imaging, 2019-10, Vol.12 (10), p.2085-2087

2019

Link zum Volltext

Verfügbarkeit prüfen

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer

NPJ breast cancer, 2022-05, Vol.8 (1), p.63-63, Article 63

2022

Link zum Volltext

Verfügbarkeit prüfen

Decision-Making About Tamoxifen in Women at High Risk for Breast Cancer: Clinical and Psychological Factors

Journal of clinical oncology, 2004-12, Vol.22 (24), p.4951-4957

2004

Link zum Volltext

Verfügbarkeit prüfen

Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers

Cancer, 2020-01, Vol.126 (2), p.271-280

2020

Link zum Volltext

Verfügbarkeit prüfen

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation

British journal of cancer, 2019-07, Vol.121 (1), p.15-21

2019

Link zum Volltext

Verfügbarkeit prüfen

Altered Proliferation and Differentiation Properties of Primary Mammary Epithelial Cells from BRCA1 Mutation Carriers

Cancer research (Chicago, Ill.), 2009-02, Vol.69 (4), p.1273-1278

2009

Link zum Volltext

Verfügbarkeit prüfen

Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk‐based testing of those older than 60 years

Cancer, 2021-03, Vol.127 (6), p.828-833

2021

Link zum Volltext

Verfügbarkeit prüfen

Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Journal of clinical oncology, 2019-09, Vol.37 (25), p.2189-2192

2019

Link zum Volltext

Verfügbarkeit prüfen

Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

Journal of clinical oncology, 2021-08, Vol.39 (24), p.2720-2731

2021

Link zum Volltext

Verfügbarkeit prüfen

How to manage patients with moderate-risk germline mutations

Clinical advances in hematology & oncology, 2018-02, Vol.16 (2), p.97

Tung, Nadine M

2018

Link zum Volltext

Verfügbarkeit prüfen

Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier

The breast journal, 2020-08, Vol.26 (8), p.1506-1512

2020

Link zum Volltext

Verfügbarkeit prüfen

Refining Risk Assessment in Women With Benign Breast Disease: An Ongoing Dilemma

JNCI : Journal of the National Cancer Institute, 2017-10, Vol.109 (10)

2017

Link zum Volltext

Verfügbarkeit prüfen

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

Clinical cancer research, 2022-11, Vol.28 (21), p.4714-4723

2022

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies

The oncologist (Dayton, Ohio), 2023-07, Vol.28 (7), p.565-574

2023

Link zum Volltext

Verfügbarkeit prüfen

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

Journal of clinical oncology, 2018-11, Vol.36 (31), p.3134-3143

2018

Link zum Volltext

Verfügbarkeit prüfen

Reply to S.M. Sorscher and M.J. Hall et al

Journal of clinical oncology, 2016-12, Vol.34 (34), p.4187-4188

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 185

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(184)
Mit Volltextzugriff
(171)

Publikationsform

Artikel
(184)
Texte
(1)

Sprache

Englisch
(185)
Japanisch
(23)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

BRCA1/2 testing: therapeutic implications for breast cancer management

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline

Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer

Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes

Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update

Noncontrast CMR for Detecting Early Myocardial Tissue Injury in a Swine Model of Anthracycline-Induced Cardiotoxicity

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer

Decision-Making About Tamoxifen in Women at High Risk for Breast Cancer: Clinical and Psychological Factors

Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation

Altered Proliferation and Differentiation Properties of Primary Mammary Epithelial Cells from BRCA1 Mutation Carriers

Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk‐based testing of those older than 60 years

Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

How to manage patients with moderate-risk germline mutations

Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier

Refining Risk Assessment in Women With Benign Breast Disease: An Ongoing Dilemma

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

Reply to S.M. Sorscher and M.J. Hall et al

Suchergebnisse filtern